CO5280087A1 - Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa - Google Patents
Composiciones farmaceuticas de inhibidores de la glucogenofosforilasaInfo
- Publication number
- CO5280087A1 CO5280087A1 CO01021769A CO01021769A CO5280087A1 CO 5280087 A1 CO5280087 A1 CO 5280087A1 CO 01021769 A CO01021769 A CO 01021769A CO 01021769 A CO01021769 A CO 01021769A CO 5280087 A1 CO5280087 A1 CO 5280087A1
- Authority
- CO
- Colombia
- Prior art keywords
- chain
- helix
- propeller
- glucogenophosphorilase
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Una composición farmacéutica que comprende un inhibidor de la glucógeno-fosforilasa y un polímero que aumenta la concentración, en la que una porción de dicho inhibidor de la glucógeno-fosforilasa se une a una porción o a todas las porciones de los siguientes residuos de una enzima glucógeno-fosforilasa:Estructura secundariaOriginal Número de residuo 13-23hélice a1 24-37vuelta 38-39, 43, 46-47hélice a2 48-66, 69-70, 73-74, 76-78 79-80cadena ß1 81-86 87-88cadena ß2 89-92 93hélice a3 94-102 103hélice a4 104-115 116-117hélice a5 118-124 125-128cadena ß3 129-131 132-133hélice a6 134-150 151-152cadena ß4 153-160 161cadena ß4b 162-163 164-166cadena ß5 167-171 172-173cadena ß6 174-178 179-190cadena ß7 191-192 194,197cadena ß8 198-209 210-211cadena ß9 212-216cadena ß10 219-226, 228-232 233-236cadena ß11 237-239, 241,243-247 248-260hélice a7 261-276cadena ß11b 277-281vuelta inversa 282-289hélice a8 290-304.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18994200P | 2000-03-16 | 2000-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5280087A1 true CO5280087A1 (es) | 2003-05-30 |
Family
ID=22699402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01021769A CO5280087A1 (es) | 2000-03-16 | 2001-03-16 | Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20010053778A1 (es) |
| EP (1) | EP1263414A1 (es) |
| JP (1) | JP2003526654A (es) |
| KR (1) | KR20020081445A (es) |
| CN (1) | CN1418089A (es) |
| AP (1) | AP2002002621A0 (es) |
| AR (1) | AR027656A1 (es) |
| AU (1) | AU2001242669A1 (es) |
| BG (1) | BG107037A (es) |
| BR (1) | BR0109189A (es) |
| CA (1) | CA2403241A1 (es) |
| CO (1) | CO5280087A1 (es) |
| CZ (1) | CZ20022955A3 (es) |
| EA (1) | EA200200858A1 (es) |
| EE (1) | EE200200530A (es) |
| HU (1) | HUP0204583A2 (es) |
| IL (1) | IL151320A0 (es) |
| IS (1) | IS6508A (es) |
| MA (1) | MA26882A1 (es) |
| MX (1) | MXPA02009097A (es) |
| NO (1) | NO20024386L (es) |
| OA (1) | OA12232A (es) |
| PA (1) | PA8513601A1 (es) |
| PE (1) | PE20011184A1 (es) |
| PL (1) | PL360780A1 (es) |
| SK (1) | SK12622002A3 (es) |
| SV (1) | SV2002000343A (es) |
| TN (1) | TNSN01040A1 (es) |
| TR (1) | TR200202184T2 (es) |
| WO (1) | WO2001068055A1 (es) |
| YU (1) | YU67202A (es) |
| ZA (1) | ZA200207290B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357470A1 (en) * | 1999-12-23 | 2004-07-26 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| US20030170309A1 (en) * | 2001-06-22 | 2003-09-11 | Babcock Walter C. | Pharmaceutical compositions containing polymer and drug assemblies |
| BR0210518A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de drogas e polìmeros neutros |
| TNSN03138A1 (en) | 2001-06-22 | 2005-12-23 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT |
| IL162819A0 (en) | 2002-02-01 | 2005-11-20 | Pfizer Prod Inc | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
| JP2005523260A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法 |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| WO2005065657A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
| EP1725555B1 (en) | 2004-03-08 | 2010-10-06 | Prosidion Ltd. | Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase |
| WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
| DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
| JP6224712B2 (ja) | 2012-08-24 | 2017-11-01 | ダウ グローバル テクノロジーズ エルエルシー | 高分子量および均一性の新規エステル化セルロースエーテル |
| HRP20211423T1 (hr) | 2012-09-11 | 2022-01-21 | Medivation Prostate Therapeutics Llc | Formulacije enzalutamida |
| US9670158B2 (en) * | 2013-07-19 | 2017-06-06 | Siga Technologies, Inc. | Amorphous tecovirimat preparation |
| CN103709171B (zh) * | 2014-01-20 | 2015-09-16 | 武汉大学 | 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法 |
| CA2987867C (en) | 2015-06-09 | 2023-06-27 | Capsugel Belgium Nv | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CN112442022B (zh) * | 2019-09-02 | 2022-05-20 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
| US11291701B1 (en) * | 2021-02-04 | 2022-04-05 | Seed Edibles | Orally disintegrating, sublingual and buccal formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0832066T3 (da) * | 1995-06-06 | 2001-11-19 | Pfizer | Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer |
| EP0832065B1 (en) * | 1995-06-06 | 2001-10-10 | Pfizer Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
-
2001
- 2001-03-14 PE PE2001000246A patent/PE20011184A1/es not_active Application Discontinuation
- 2001-03-14 AR ARP010101185A patent/AR027656A1/es not_active Application Discontinuation
- 2001-03-14 US US09/805,828 patent/US20010053778A1/en not_active Abandoned
- 2001-03-15 TN TNTNSN01040A patent/TNSN01040A1/fr unknown
- 2001-03-15 SV SV2001000343A patent/SV2002000343A/es not_active Application Discontinuation
- 2001-03-16 YU YU67202A patent/YU67202A/sh unknown
- 2001-03-16 AU AU2001242669A patent/AU2001242669A1/en not_active Abandoned
- 2001-03-16 BR BR0109189-1A patent/BR0109189A/pt not_active Application Discontinuation
- 2001-03-16 CZ CZ20022955A patent/CZ20022955A3/cs unknown
- 2001-03-16 OA OA1200200290A patent/OA12232A/en unknown
- 2001-03-16 WO PCT/IB2001/000394 patent/WO2001068055A1/en not_active Application Discontinuation
- 2001-03-16 SK SK1262-2002A patent/SK12622002A3/sk unknown
- 2001-03-16 JP JP2001566619A patent/JP2003526654A/ja active Pending
- 2001-03-16 TR TR2002/02184T patent/TR200202184T2/xx unknown
- 2001-03-16 KR KR1020027012009A patent/KR20020081445A/ko not_active Application Discontinuation
- 2001-03-16 CO CO01021769A patent/CO5280087A1/es not_active Application Discontinuation
- 2001-03-16 EE EEP200200530A patent/EE200200530A/xx unknown
- 2001-03-16 EP EP01915586A patent/EP1263414A1/en not_active Withdrawn
- 2001-03-16 PL PL36078001A patent/PL360780A1/xx not_active Application Discontinuation
- 2001-03-16 CN CN01806619A patent/CN1418089A/zh active Pending
- 2001-03-16 MX MXPA02009097A patent/MXPA02009097A/es unknown
- 2001-03-16 IL IL15132001A patent/IL151320A0/xx unknown
- 2001-03-16 HU HU0204583A patent/HUP0204583A2/hu unknown
- 2001-03-16 PA PA20018513601A patent/PA8513601A1/es unknown
- 2001-03-16 CA CA002403241A patent/CA2403241A1/en not_active Abandoned
- 2001-03-16 AP APAP/P/2002/002621A patent/AP2002002621A0/en unknown
- 2001-03-16 EA EA200200858A patent/EA200200858A1/ru unknown
-
2002
- 2002-08-16 IS IS6508A patent/IS6508A/is unknown
- 2002-08-26 BG BG107037A patent/BG107037A/bg unknown
- 2002-09-11 ZA ZA200207290A patent/ZA200207290B/xx unknown
- 2002-09-11 MA MA26810A patent/MA26882A1/fr unknown
- 2002-09-13 NO NO20024386A patent/NO20024386L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020081445A (ko) | 2002-10-26 |
| NO20024386D0 (no) | 2002-09-13 |
| IL151320A0 (en) | 2003-04-10 |
| YU67202A (sh) | 2006-01-16 |
| SK12622002A3 (sk) | 2004-02-03 |
| TR200202184T2 (tr) | 2003-01-21 |
| NO20024386L (no) | 2002-11-13 |
| PL360780A1 (en) | 2004-09-20 |
| CN1418089A (zh) | 2003-05-14 |
| MXPA02009097A (es) | 2003-03-12 |
| US20010053778A1 (en) | 2001-12-20 |
| AR027656A1 (es) | 2003-04-09 |
| AU2001242669A1 (en) | 2001-09-24 |
| PA8513601A1 (es) | 2004-08-31 |
| EP1263414A1 (en) | 2002-12-11 |
| BG107037A (bg) | 2003-04-30 |
| IS6508A (is) | 2002-08-16 |
| PE20011184A1 (es) | 2001-11-15 |
| BR0109189A (pt) | 2003-05-27 |
| CA2403241A1 (en) | 2001-09-20 |
| EE200200530A (et) | 2004-04-15 |
| MA26882A1 (fr) | 2004-12-20 |
| HUP0204583A2 (hu) | 2003-04-28 |
| OA12232A (en) | 2006-05-10 |
| SV2002000343A (es) | 2002-07-03 |
| CZ20022955A3 (cs) | 2003-09-17 |
| ZA200207290B (en) | 2003-09-11 |
| AP2002002621A0 (en) | 2002-09-30 |
| WO2001068055A1 (en) | 2001-09-20 |
| EA200200858A1 (ru) | 2003-02-27 |
| TNSN01040A1 (fr) | 2005-11-10 |
| JP2003526654A (ja) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5280087A1 (es) | Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa | |
| AR037951A1 (es) | Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada | |
| EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
| PE20080093A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| PE20070583A1 (es) | Formulacion que comprende un inhibidor de dipeptidil-peptidasa iv y metformina | |
| EA200702498A1 (ru) | N-(пиридин-2-ил)сульфонамидные производные | |
| BR9814698A (pt) | Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| PE20050130A1 (es) | Compuestos organicos | |
| AR045173A1 (es) | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio | |
| PE20100363A1 (es) | Composiciones que comprenden nucleosidos | |
| NO20012000D0 (no) | N-(2-aryl-propionyl)-sulfonamider og farmasöytiske sammensetninger som inneholder dem | |
| NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| NO20073764L (no) | Sammensetninger for behandling av HCV | |
| NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
| AR036906A1 (es) | Compuestos de imidazopiridin como moduladores del receptor 5-ht4 | |
| NO20045042L (no) | 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer | |
| CY1107939T1 (el) | Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη | |
| ES2182903T3 (es) | Derivados heterociclicos utiles en el tratamiento de enfermedades alergicas o reumaticas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| HUP0103203A2 (hu) | Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0301830A2 (hu) | FBP-áz inhibitorok és antidiabetikus szerek kombinációját tartalmazó gyógyszerkészítmény, amely cukorbetegség kezelésére alkalmas | |
| EA200400708A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
| ES2099551T3 (es) | Nuevos 19-nor-esteroides que tienen en posicion 11 beta una cadena de fenoxialquilsulfonamida o fenoxialquilsulfonilurea, procedimiento y productos intermedios de preparacion, aplicacion como medicamentos y composicion farmaceutica que los contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |